Horizon Pharma Inc. (NASDAQ:HZNP)’s share price was up 2.2% during trading on Thursday . The company traded as high as $18.15 and last traded at $17.89, with a volume of 2,109,744 shares traded. The stock had previously closed at $17.51.

HZNP has been the topic of a number of analyst reports. Vetr upgraded shares of Horizon Pharma from a “buy” rating to a “strong-buy” rating and set a $21.00 price objective on the stock in a research report on Monday, June 13th. Zacks Investment Research cut shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, April 20th. TheStreet upgraded shares of Horizon Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, March 10th. Guggenheim reiterated a “buy” rating on shares of Horizon Pharma in a research report on Tuesday, May 10th. Finally, Piper Jaffray Cos. reiterated a “buy” rating and set a $44.00 price target on shares of Horizon Pharma in a research report on Wednesday, April 13th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $29.93.

The stock has a 50-day moving average of $16.85 and a 200 day moving average of $17.12. The stock has a market cap of $2.92 billion and a PE ratio of 236.23.

Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported $0.34 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.30 by $0.04. The company earned $204.70 million during the quarter, compared to analysts’ expectations of $197.73 million. During the same period in the prior year, the business earned $0.18 EPS. The company’s quarterly revenue was up 80.9% on a year-over-year basis. Analysts forecast that Horizon Pharma Inc. will post $2.35 EPS for the current year.

In related news, Director Virinder Nohria sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, June 15th. The shares were sold at an average price of $17.69, for a total value of $442,250.00. Following the transaction, the director now owns 189,836 shares of the company’s stock, valued at approximately $3,358,198.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

A number of hedge funds and institutional investors have bought and sold shares of the stock. Teacher Retirement System of Texas increased its position in Horizon Pharma by 87.4% in the fourth quarter. Teacher Retirement System of Texas now owns 2,136,961 shares of the biopharmaceutical company’s stock worth $46,308,000 after buying an additional 996,761 shares during the period. Hodges Capital Management Inc. increased its position in Horizon Pharma by 4.1% in the fourth quarter. Hodges Capital Management Inc. now owns 1,571,794 shares of the biopharmaceutical company’s stock worth $34,061,000 after buying an additional 61,454 shares during the period. Tekla Capital Management LLC increased its position in Horizon Pharma by 130.2% in the fourth quarter. Tekla Capital Management LLC now owns 749,900 shares of the biopharmaceutical company’s stock worth $16,250,000 after buying an additional 424,100 shares during the period. CAM Group Holding A S acquired a new position in Horizon Pharma during the fourth quarter worth approximately $14,335,000. Finally, Dimensional Fund Advisors LP increased its position in Horizon Pharma by 104.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 557,772 shares of the biopharmaceutical company’s stock worth $12,089,000 after buying an additional 284,359 shares during the period.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.